Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $206 from $204 and keeps a Neutral rating on the shares after its Q3 earnings beat. The company’s pipeline is an upside lever with multiple data catalysts coming – including KB408-AATD by 2024-end, KB707-solid tumor by 2024-end, KB407-CF in the first half of 2025, and ophthalmic B-VEC in 2025, the analyst tells investors in a research note. Citi adds that while it currently heavily risk-adjusts these programs, but achieving initial proof of concept could merit “substantial de-risking and a thesis re-assessment”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech price target raised to $212 from $208 at Chardan
- Krystal Biotech reports Q3 EPS 91c, consensus 90c
- Krystal Biotech sees FY24 non-GAAP R&D, SG&A expense $115M-$125M
- Is KRYS a Buy, Before Earnings?
- Intellia Therapeutics price target lowered to $64 from $80 at Stifel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
